Incyte secures an exclusive option to acquire Prelude’s mutant selective JAK2V617F JH2 inhibitor program Mutant selective JAK2V617F JH2 inhibitors have disease-modifying potential in treating patients living with myeloproliferative neoplasms (MPNs) Prelude to receive a $35 million upfront payment and$25 million strategic equity investment, $100 million if Incyte were to exercise the option to acquire the program, and up to$775 million in additional potential milestones plus royalties on net salesPrelude w ...